ORIC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Oric Pharmaceuticals Inc (ORIC) is not a strong buy at this moment for a beginner investor with a long-term horizon. While the stock has potential upside in the long term due to its promising pipeline, the lack of immediate positive catalysts, weak financial performance, and hedge fund selling trends suggest caution. It is better to hold off on investing until clearer signs of growth or momentum emerge.
The technical indicators are neutral to slightly bearish. The MACD histogram is negative and contracting, RSI is neutral at 40.143, and moving averages are converging. The stock is trading close to its pivot level of 10.574, with support at 9.883 and resistance at 11.265.
Analysts have a generally positive outlook on the company's lead asset ORIC-944, which has potential in the prostate cancer market. Multiple analysts have initiated coverage with Overweight or Buy ratings, and price targets range from $16 to $25, suggesting significant upside potential. The upcoming clinical update in Q1 could be a value creation event.
Hedge funds are aggressively selling, with a 496.64% increase in selling activity over the last quarter. Financial performance is weak, with declining net income (-5.73% YoY) and EPS (-32.65% YoY). No recent news or congress trading data to support a bullish sentiment.
The company's financials for Q3 2025 show no revenue growth (0% YoY) and a net income drop to -$32.59M (-5.73% YoY). EPS also fell significantly by -32.65% YoY, indicating weak financial health.
Analysts are optimistic about the company's pipeline, particularly ORIC-944, with multiple Overweight and Buy ratings. Price targets range from $16 to $25, implying potential upside. However, the stock's performance hinges on the success of its clinical trials and updates.
